Subtypes of Epstein-Barr virus in HIV-1-positive and HIV-1-negative patients with Hodgkin's disease (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Subtypes of Epstein-Barr virus in HIV-1-positive and HIV-1-negative patients with Hodgkin's disease (Meeting abstract).

EACR-12: 12th Biennial Meeting of the European Association for Cancer Research. April 4-7, 1993, Brussels, Belgium, 1993.. Unique Identifier : AIDSLINE ICDB/94697510
De Re V; De Vita S; Marzotto A; Gloghini A; Carbone A; Uccini S; Scarpa A; and Boiocchi M; Div. of Experimental Oncology, Aviano, Italy

Abstract: Considerable evidence suggests that EBV has a role in the pathogenesis of Hodgkin's disease (HD). In immunocompetent hosts type 2 EBV is considered to be a much less potent transformer of lymphocytes than type 1 virus strain. However, type 2 EBV may be involved in the pathogenesis of non-Hodgkin's lymphomas arising in immunocompromised patients (ie, those with HIV-1 or malarial infection). To determine whether type 2 EBV may also play a role in similar patients developing HD, we characterized EBV subtypes, using the PCR technology, in 36 tumor samples (previously demonstrated to be EBV-positive by amplification of the IR3 genome sequence common to both EBV strains) from 10 HIV-1-positive patients as well as from a control population of 26 HIV-1-negative patients. Type 2 EBV was detected in 5 samples from HIV-1-positive patients, and in only 1 sample from the HIV-1-negative group. DNA of one HIV-1-positive patient and DNA of one HIV-1-negative patient was positive for both EBV type 1 and EBV type 2. DNA sequence analysis of EBNA-2 region indicated the concomitant presence of both EBV type 1 and EBV type 2 expansions and excluded a possible 'hybrid-recombinant' in these two tumor samples. A biclonal EBV tumor infection was also detected by Southern blot in two additional HIV-1-negative cases, both clones belonging, this time, to type 1 virus strain. In six EBV-positive cases (all from HIV-1-negative patients), characterization of the virus could not be performed presumably on account of deletion including EBNA-2 region. Our results indicate that in HIV-1-infected patients type 2 EBV presents a transforming ability that is roughly similar to that shown by type 1 virus strain also in patients developing HD.

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS/*MICROBIOLOGY Antigens, Viral/GENETICS DNA-Binding Proteins/GENETICS Gene Amplification Genome, Viral *Herpesvirus 4, Human/GENETICS Hodgkin's Disease/COMPLICATIONS/GENETICS/*MICROBIOLOGY Human HIV Seropositivity/GENETICS/*MICROBIOLOGY ABSTRACT
941230
M94C4338

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .